0LB2.LSE Supernus Pharmaceuticals, Inc.

Healthcare Drug Manufacturers - Specialty & Generic London Exchange
- USD
Market cap
-
P/E
32.5x
P/B
-
ROE
-5.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0LB2.LSE undervalued?

Graham number

The Graham number of Supernus Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Supernus Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Supernus Pharmaceuticals, Inc. yet.

Supernus Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product …

Full company profile